公开(公告)号：US20240148775A1

公开(公告)日：2024-05-09

申请号：US18547071

申请日：2022-02-25

Applicant: Osaka University

Inventor： Masahito SHIMOJO ,  Satoshi OBIKA ,  Keishiro MISHIMA ,  Misa YOSHIDA

IPC: A61K31/713 ,  A61P35/00 ,  C12N15/113

CPC classification number: A61K31/713 ,  A61P35/00 ,  C12N15/113

Abstract: An oligonucleotide or a pharmacologically acceptable salt thereof according to the present invention contains a nucleotide sequence complementary to a continuous sequence of at least 12 bases in a target region constituted by a base sequence of SEQ ID No. 1, and induces N-exon skipping in human REST pre-mRNA processing. Such oligonucleotides are useful for manufacturing medicines for treatment of cancer, for example.

公开(公告)号：US20210277398A1

公开(公告)日：2021-09-09

申请号：US17261653

申请日：2019-07-31

Applicant: Osaka University ,  National Institutes of Biomedical Innovation, Health and Nutrition ,  Luxna Biotech Co., Ltd.

Inventor： Masahito SHIMOJO ,  Satoshi OBIKA ,  Yuya KASAHARA ,  Takao SUZUKI ,  Masaki YAMAGAMI ,  Tadashi UMEMOTO

IPC: C12N15/113

Abstract: Disclosed is an oligonucleotide or a pharmacologically acceptable salt thereof, wherein the oligonucleotide comprises at least one defined nucleoside structure, can bind to a human nSR100 gene and has human nSR100 expression inhibiting activity. The oligonucleotide has a length of 12 to 20 mer, and is complementary to a defined target region. Further, disclosed is an nSR100 gene expression inhibitor and a cancer therapeutic agent containing the oligonucleotide or the pharmacologically acceptable salt thereof. The cancer therapeutic agent is used for treatment of small cell lung cancer, prostate cancer, or breast cancer.